Related Experiment Videos

Effects of metoprolol in chagasic patients with severe congestive heart failure

Diego F Dávila1, Francisco Angel, Gabriela Arata de Bellabarba

  • 1Instituto de Investigaciones Cardiovasculares, Departamento de Fisiopatología, Universidad de Los Andes, Apartado Postal 590, Mérida, Venezuela. diegod@ing.ula.ve

International Journal of Cardiology
|September 5, 2002
PubMed

Insights

Metoprolol, a beta-blocker, significantly improved heart function and clinical status in patients with severe congestive heart failure due to Chagas disease. This treatment offers a promising therapeutic option for managing this condition.

Area of Science:

  • Cardiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Congestive heart failure (CHF) in Chagas disease is often linked to left ventricular dysfunction and sympathetic nervous system overactivity.
  • Beta-blockers are established treatments for CHF stemming from left ventricular dysfunction.

Purpose of the Study:

  • To evaluate the efficacy of metoprolol in improving left ventricular function and clinical status in chagasic patients experiencing severe CHF.

Main Methods:

  • Nine chagasic patients with severe CHF received metoprolol, starting at 5 mg daily and increasing weekly.
  • Patients were already on digitalis, diuretics, and ACE inhibitors.

Main Results:

  • Metoprolol treatment improved New York Heart Association functional class, reduced heart rate, and increased systolic blood pressure.
  • Left ventricular ejection fraction and systolic diameter showed significant improvements after 10 weeks of metoprolol therapy.

Conclusions:

  • Beta-blockers, specifically metoprolol, demonstrate a beneficial effect on clinical status and left ventricular function in chagasic patients with severe CHF.
  • Metoprolol represents a promising therapeutic strategy for managing Chagasic cardiomyopathy.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...